Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Myelodysplasias

Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia

Abstract

Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative disorder of early childhood. In all, 21 patients with JMML who received donor leukocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) for either mixed chimerism (MC, n=7) or relapse (n=14) were studied. Six patients had been transplanted from an HLA-matched sibling and 15 from other donors. Six of the 21 patients (MC: 3/7 patients; relapse: 3/14 patients) responded to DLI. Response rate was significantly higher in patients receiving a higher total T-cell dose (1 × 107/kg) and in patients with an abnormal karyotype. None of the six patients receiving DLI from a matched sibling responded. Response was observed in five of six patients who did and in one of 15 children who did not develop acute graft-versus-host disease following DLI (P=0.01). The overall outcome was poor even for the responders. Only one of the responders is alive in remission, two relapsed, and three died of complications. In conclusion, this study shows that some cases of JMML may be sensitive to DLI, this providing evidence for a graft-versus-leukemia effect in JMML. Infusion of a high number of T cells, strategies to reduce toxicity, and cytoreduction prior to DLI may improve the results.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Niemeyer CM, Aricò M, Basso G, Biondi A, Cantù-Rajnoldi A, Creutzig U et al. Chronic myelomonocytic leukemia in childhood: a report of 110 cases. Blood 1997; 89: 3534–3543.

    CAS  Google Scholar 

  2. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277–282.

    Article  CAS  Google Scholar 

  3. Hasle H, Niemeyer C . Myelodysplastic syndrome and juvenile myelomonocytic leukemia in children. In: Bennett JM (ed), The Myelodysplastic Syndromes. New York, Basel: Marcel Dekker, Inc., 2002, pp 299–344.

    Google Scholar 

  4. Flotho C, Valcamonica S, Mach-Pascula S, Schmahl G, Corral L, Ritterbach J et al. Ras mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999; 13: 32–37.

    Article  CAS  Google Scholar 

  5. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998; 92: 267–272.

    CAS  Google Scholar 

  6. Tartaglia M, Niemeyer CM, Song X, Buechner J, Hählen K, Hasle H et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148–150.

    Article  CAS  Google Scholar 

  7. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomoncytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005; 105: 410–419.

    Article  CAS  Google Scholar 

  8. Manabe A, Okamura J, Yumura-Yagi K, Akiyama Y, Sako M, Uchiyama H et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002; 16: 645–649.

    Article  CAS  Google Scholar 

  9. Locatelli F, Niemeyer C, Angelucci E, Bender-Götze C, Burdach S, Ebell W et al. Allogenic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997; 15: 566–573.

    Article  CAS  Google Scholar 

  10. Smith FO, King R, Nelson G, Wagner JE, Robertson KA, Sanders JE et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 2002; 116: 716–724.

    Article  Google Scholar 

  11. Matthes-Martin S, Mann G, Peters C, Lion T, Fritsch G, Haas OA et al. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. Bone Marrow Transplant 2000; 26: 377–382.

    Article  CAS  Google Scholar 

  12. Worth A, Rao K, Webb D, Chessells J, Passmore J, Veys P . Successful treatment of juvenile myelomonocytic leukemia relapsing post stem cell transplant using donor lymphocyte infusion. Blood 2003; 101: 1713–1714.

    Article  CAS  Google Scholar 

  13. Pulsipher MA, Adams RH, Asch J, Petersen FB . Successful treatment of JMML relapsed after unrelated allogeneic transplant with cytoreduction followed by DLI and interferon-alpha: evidence for a graft-versus-leukemia effect in non-monosomy-7 JMML. Bone Marrow Transplant 2004; 33: 113–115.

    Article  CAS  Google Scholar 

  14. Neudorf S, Nourani A, Kempert P, Shen V, Sender L, Kirov I . Chemotherapy and donor leukocyte infusions for relapsed juvenile myelomonocytic leukemia (JMML). Bone Marrow Transplant 2004; 33: 1069.

    Article  CAS  Google Scholar 

  15. Bader P, Holle W, Klingebiel T, Handgretinger R, Niethammer D, Beck J . Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res 1996; 16: 1759–1763.

    CAS  Google Scholar 

  16. Lion T, Muller-Berat N . Chimerism testing after allogeneic stem cell transplantation: importance of timing and optimal technique for chimerism testing in different clinical-biological situations. Leukemia 1999; 13: 2059.

    Article  CAS  Google Scholar 

  17. Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055–1060.

    Article  CAS  Google Scholar 

  18. Allen RC, Graves G, Budowle B . Polymerase chain-reaction amplification products separated on rehydratable polyacrylamide gels and stained with silver. Biotechniques 1989; 7: 736–744.

    CAS  PubMed  Google Scholar 

  19. Formankova R, Honzatkova L, Moravcova J, Sieglova Z, Dvorakova R, Nadvornikova S et al. Prediction and reversion of post-transplant relapse in patients with chronic myeloid leukemia using mixed chimerism and residual disease detection and adoptive immunotherapy. Leukemia Res 2000; 24: 339–347.

    Article  CAS  Google Scholar 

  20. de Weger RA, Tilanus MGJ, Scheidel KC, van den Tweel JG, Verdonck LF . Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats. Br J Haematol 2000; 110: 647–653.

    Article  CAS  Google Scholar 

  21. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  22. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  23. Fisher RA . Statistical Methods and Scientific Inference. Edinburgh: Oliver and Boyd ed., 1956.

    Google Scholar 

  24. Mann HB, Whitney DR . On a test of whether one or two random variables ist stochastically larger than the other. Ann Math Stat 1947; 18: 50–60.

    Article  Google Scholar 

  25. Rassam SM, Katz F, Chessells JM, Morgan G . Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect? Bone Marrow Transplant 1993; 11: 247–250.

    CAS  PubMed  Google Scholar 

  26. Kressler EJ, Haas OA, Konig M, Mann G, Mayer H, Peters C et al. Extramedullary relapse despite graft-versus-leukemia effect after bone marrow transplantation in a girl with juvenile myelomonocytic leukemia. Leukemia Lymphoma 1999; 33: 597–600.

    Article  CAS  Google Scholar 

  27. Orchard PJ, Miller JS, McGlennen R, Davies SM, Ramsay NK . Graft-versus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia. Bone Marrow Transplant 1998; 22: 201–203.

    Article  CAS  Google Scholar 

  28. MacMillan ML, Davies SM, Orchard PJ, Ramsay NK, Wagner JE . Haemopoietic cell transplantation in children with juvenile myelomonocytic leukaemia. Br J Haematol 1998; 103: 552–558.

    Article  CAS  Google Scholar 

  29. Ohta H, Kawai M, Sawada A, Tokimasa S, Fujisaki H, Matsuda Y et al. Juvenile myelomonocytic leukemia relapsing after allogeneic bone marrow transplantation successfully treated with interferon-alpha. Bone Marrow Transplant 2000; 26: 681–683.

    Article  CAS  Google Scholar 

  30. Lutz P, Zix-Kieffer I, Souillet G, Bertrand Y, Dhooge Y, Rubie H et al. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC childrens leukemia cooperative group (CLCG). Bone Marrow Transplant 1996; 18: 1111–1116.

    CAS  Google Scholar 

  31. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA . Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003; 121: 758–767.

    Article  Google Scholar 

  32. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  Google Scholar 

  33. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    CAS  Google Scholar 

  34. van Rhee F, Savage D, Blackwell J, Orchard K, Dazzi F, Lin F et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998; 21: 1055–1061.

    Article  CAS  Google Scholar 

  35. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712–2716.

    CAS  PubMed  Google Scholar 

  36. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195–2204.

    CAS  Google Scholar 

  37. Nadal E, Fowler A, Kanfer E, Apperley J, Goldman J, Dazzi F . Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Experimental Hematology 2004; 32: 218–223.

    Article  CAS  Google Scholar 

  38. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377–3383.

    CAS  PubMed  Google Scholar 

  39. Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487–495.

    Article  CAS  Google Scholar 

  40. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696–1705.

    Article  Google Scholar 

  41. Bernard F, Thomas C, Emile JF, Hercus T, Cassinat B, Chomienne C et al. Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood 2002; 99: 2615–2616.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the affected individuals and their families who participated in this study, the physicians who referred the patients, Dr I Baumann and Dr G Kerndrup for reference morphology review, Dr O Haas, Dr J Harbott, Dr K Michalova and Dr B Beverloo for reference review of cytogenetic studies. This work was supported by the Deutsche José Carreras Leukämie-Stiftung e.V., München, Germany, the Deutsche Krebshilfe, Bonn, Germany, and the Alexander von Humboldt-Stiftung, Bonn, Germany.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to A Yoshimi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshimi, A., Bader, P., Matthes-Martin, S. et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 19, 971–977 (2005). https://doi.org/10.1038/sj.leu.2403721

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403721

Keywords

This article is cited by

Search

Quick links